Start 30 days free, no card. Full Pro access for a month, then decide. Start free
Analyst
Dan Hurren
Period: Reporting periods mapped to calendar 2024 Q3 – 2026 Q2 (8 quarters; questions recorded in 7).
- Questions
- 7on tracked calls
- Challenge rate
- 29%2 of 7 questionsLimited sample
- Companies
- 1questioned at least once
- Reporting periods
- 7with questions
These figures cover the whole profile: every tracked question, all reporting periods.
How to read these numbers
Challenge rate is the share of questions that pushed back, pressed for specifics or questioned management’s assumptions. It describes how questions were asked on the calls tracked here; it does not measure whether any view turned out to be right.
Rounding. Rates are rounded to whole percentages, so a small share can show as 0% even when some questions were challenging. The count beside each rate is exact; “none of N questions” means no question was challenging.
No questions recorded. “—” means there is nothing to calculate: no questions were recorded for that period on the calls tracked here. It does not mean there was no activity.
Fewer than 3 questions. A company-level rate is withheld when fewer than 3 questions were recorded for that company; the questions are still counted everywhere else.
Small samples. Profiles with fewer than 10 questions are marked Limited sample.
Reporting periods. Questions are grouped by the calendar quarter each company’s fiscal reporting period maps to, not by the date of the call. Periods without a calendar mapping are listed separately under their fiscal label.
Questions asked
Grouped by company, most questions first. Open a company to read its questions, newest reporting period first.
Showing 7 of 7 questions from 1 company
RMDResMed7 questions · 7 reporting periods · 2 of 7 challenging
Calendar 2026 Q2
did you talk about talk to OpEx within your FY 2027 guidance? I'm only asking because it looks like R&D stepped up
Show response
Mick framed the R&D step-up as innovation investment; Aaron leaned on OpEx flexibility under the new total-EPS guide without a specific driver for the Q4 jump.
Calendar 2025 Q4
The SG&A growth is uncharacteristically ahead of revenue growth
Show response
Brett explained VirtuOx acquisition drove SG&A above revenue growth. Excluding VirtuOx, SG&A growth was high single digits, tracking close to revenue. Additional promotional campaigns including China Singles Day contributed.
Calendar 2025 Q3
I'm not sure you actually gave us your thoughts on what you think the range of outcomes will be
Show response
Mick expressed confidence that sophisticated HME base will bid appropriately based on 2021 experience when bids were right in line with costs. Emphasized sleep apnea treatment delivers healthcare system cost savings, strengthening advocacy position.
Calendar 2025 Q2
can you just talk through the elements of that gross margin guidance? And maybe touch on the FX
Show response
Brett noted almost half of Q4 sequential margin improvement was FX-driven, remainder from component cost improvements, sea-to-air freight ratio now at pre-COVID levels, and AS10-to-AS11 transition. Mick added new Chief Supply Chain Officer bringing science-based approach.
Calendar 2025 Q1
I was just wondering if that exemption will apply or extend to all CPAP and therapy coming into the US
Show response
Mick traced tariff exemption history from 1982 Reagan admin through 2009 CBP ruling to 2025 reaffirmation. Noted competitors importing from China face triple-digit tariffs. ResMed imports from Australia and Singapore.
Calendar 2024 Q4
Can you just talk us through any other FX impacts down the P&L as we've seen the strength of the U.S. dollar?
Show response
Brett explained approximately 30bp sequential gross margin headwind from FX, with -$0.02 EPS impact. Q3 expects neutral gross margin impact with slight SG&A/R&D benefit from weaker AUD/SGD.
Calendar 2024 Q3
we've noticed that this term tuck-in acquisition has become very common in your commentary
Show response
Mick highlighted Snap Technologies, Somnoware, and NightOwl as successful tuck-in examples. Brett sized the range at $100M-$500M depending on strategic and cultural fit.
Challenge rate by company
Every company this analyst questioned, most questions first. A company-level rate is shown from 3 questions; below that it is withheld.
| Company | Questions | Challenge rate |
|---|---|---|
| RMD ResMed | 7 | 29%2 of 7 questions |
- RMDResMed · 7 questions29%2 of 7 questions
Activity by reporting period
Questions recorded for each calendar quarter that companies’ reporting periods map to (not the call date), with the challenge rate for that period. Periods inside the range with no questions are shown as “No questions recorded”.
| Calendar period | Questions | Challenge rate | Companies |
|---|---|---|---|
| 2024 Q3 | 1 | 0%none of 1 question | 1 |
| 2024 Q4 | 1 | 0%none of 1 question | 1 |
| 2025 Q1 | 1 | 0%none of 1 question | 1 |
| 2025 Q2 | 1 | 0%none of 1 question | 1 |
| 2025 Q3 | 1 | 0%none of 1 question | 1 |
| 2025 Q4 | 1 | 100%1 of 1 question | 1 |
| 2026 Q1 | No questions recorded | — | — |
| 2026 Q2 | 1 | 100%1 of 1 question | 1 |
- 2024 Q31 question · challenge rate 0% (none of 1 question) · 1 company
- 2024 Q41 question · challenge rate 0% (none of 1 question) · 1 company
- 2025 Q11 question · challenge rate 0% (none of 1 question) · 1 company
- 2025 Q21 question · challenge rate 0% (none of 1 question) · 1 company
- 2025 Q31 question · challenge rate 0% (none of 1 question) · 1 company
- 2025 Q41 question · challenge rate 100% (1 of 1 question) · 1 company
- 2026 Q1No questions recorded
- 2026 Q21 question · challenge rate 100% (1 of 1 question) · 1 company
Topics
Topics tagged on this analyst’s questions.
- Margin3
- Fx2
- Innovation & R&D1
- Guidance Reliability1
- Cost Pressure1
- Regulation Policy1
- Pricing1
- Trade Tariffs1
- Competitive Dynamics1
- M&A1
Show all 11 topics
- Capital Allocation1